GLP-1受体激动剂在炎症性肠病合并肥胖和/或糖尿病患者中的辅助治疗:目标试验模拟
本研究采用目标试验模拟方法,利用2018-2023年行政索赔数据库,评估司美格鲁肽或替尔泊肽对炎症性肠病合并肥胖和/或糖尿病患者的1年复发风险及安全性。结果显示,在稳定期患者中,无论背景治疗是5-氨基水杨酸还是高级治疗/免疫调节剂,启动GLP-1受体激动剂均未显著改善复发或安全结局。
要点
- 在背景5-氨基水杨酸或无IBD定向治疗患者中,GLP-1受体激动剂组与未启动组的1年复发风险无差异(7.9% vs 7.9%)。
- 在背景高级治疗和/或免疫调节剂患者中,复发风险也无显著差异(12.4% vs 15.6%)。
- 约1/3患者在1年内停用GLP-1受体激动剂,安全结局与未启动组相当。
核心结论
- 在稳定期炎症性肠病合并肥胖和/或糖尿病患者中,辅助使用司美格鲁肽或替尔泊肽未改善1年复发或安全结局。
研究设计与样本
- 目标试验模拟研究,使用2018-2023年OptumLabs Data Warehouse行政索赔数据,纳入稳定期IBD(无激素使用、无IBD相关住院或手术、IBD治疗稳定>6个月)合并肥胖和/或糖尿病的患者,分两个队列进行1:1倾向评分匹配。
主要发现
- 队列1(背景5-氨基水杨酸或无IBD定向药物):2028对匹配患者,GLP-1受体激动剂启动组与未启动组的1年复发风险分别为7.9% vs 7.9%(RR 1.01,95%CI 0.82-1.24),安全结局7.0% vs 7.9%(RR 0.88,95%CI 0.71-1.10)。
- 队列2(背景高级治疗和/或免疫调节剂):346对匹配患者,复发风险12.4% vs 15.6%(RR 0.80,95%CI 0.55-1.15),安全结局5.5% vs 6.6%(RR 0.88,95%CI 0.48-1.58)。
- 队列1中36%的患者在1年内停用GLP-1受体激动剂,队列2中为33%。
临床怎么用
- 对于稳定期IBD合并肥胖和/或糖尿病的患者,辅助使用司美格鲁肽或替尔泊肽可能不会带来IBD相关结局的额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We conducted a target trial emulation study to examine the effect of 2 glucagon-like peptide-1 receptor agonists (semaglutide and tirzepatide) on clinical outcomes in patients with inflammatory bowel diseases with obesity and/or diabetes. METHODS: We emulated a target trial of glucagon-like peptide-1 receptor agonists in eligible, stable patients with inflammatory bowel diseases (no steroid use, no inflammatory bowel disease-related hospitalization or surgery and stable dose of inflammatory bowel disease therapy for >6 months) with comorbid obesity and/or diabetes using observational data from an administrative claims database (OptumLabs Data Warehouse) between 2018 and 2023. We created 2 separate cohorts: (cohort 1) background 5-aminosalicylates or no inflammatory bowel disease-directed medications; and (cohort 2) background advanced therapies and/or immunomodulators. We compared the 1-year risk of relapse (composite of inflammatory bowel disease-related hospitalization, surgery, or prednisone use) and safety with glucagon-like peptide-1 receptor agonist initiation vs noninitiation, after 1:1 propensity score matching. RESULTS: Cohort 1: In 2028 patients initiated on glucagon-like peptide-1 receptor agonists (age, 63 ± 11 years; 63% female; 71% with ulcerative colitis) matched 1:1 to glucagon-like peptide-1 receptor agonist noninitiators, there was no difference in risk of relapse (7.9% vs 7.9%; relative risk, 1.01; 95% confidence interval, 0.82-1.24) or safety outcomes (7.0% vs 7.9%; relative risk, 0.88; 95% confidence interval, 0.71-1.10); 36% patients discontinued glucagon-like peptide-1 receptor agonists within 1 year. Cohort 2: In 346 patients initiated on glucagon-like peptide-1 receptor agonists (age, 59 ± 12 years; 62% female; 43% with ulcerative colitis) matched 1:1 to glucagon-like peptide-1 receptor agonist noninitiators, no significant difference was observed in the risk of relapse (12.4% vs 15.6%; relative risk, 0.80; 95% confidence interval, 0.55-1.15) or safety outcomes (5.5% vs 6.6%; relative risk, 0.88; 95% confidence interval, 0.48-1.58); 33% of patients discontinued glucagon-like peptide-1 receptor agonists within 1 year. CONCLUSIONS: Adjunctive treatment with semaglutide or tirzepatide does not improve outcomes in patients with stable inflammatory bowel diseases on advanced therapies and/or immunomodulators and/or 5-aminosalicylates.
引用
- Yeh KH, Ahuja D, Patel SB, et al. Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation. Clin Gastroenterol Hepatol. 2026. PMID: 42309434. doi:10.1016/j.cgh.2026.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。